IDRA-21: Difference between revisions
CSV import |
CSV import |
||
| Line 30: | Line 30: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
<gallery> | |||
File:IDRA-21.svg|IDRA-21 | |||
</gallery> | |||
Revision as of 01:08, 20 February 2025
IDRA-21 is an amplakine compound in the aniracetam family that has been studied for its potential use in the treatment of cognitive impairment. This compound, which was first synthesized in the mid-1990s, is known for its ability to enhance brain function and improve memory by modulating glutamate receptors in the brain.
History
IDRA-21 was first synthesized in the mid-1990s by a team of researchers at the University of Florida. The compound was developed as part of a larger effort to discover new drugs that could enhance brain function and improve memory. Early studies on IDRA-21 showed that it had the potential to significantly improve memory and cognitive function in both animals and humans.
Mechanism of Action
IDRA-21 acts as a positive allosteric modulator of the AMPA receptor, a type of glutamate receptor in the brain. By modulating the activity of these receptors, IDRA-21 can enhance the brain's ability to process information and improve memory. This makes it a potential treatment for conditions such as Alzheimer's disease and other forms of cognitive impairment.
Clinical Trials
While IDRA-21 has shown promise in early studies, it has not yet been approved for use in humans. Clinical trials are currently underway to determine the safety and efficacy of this compound in treating cognitive impairment. These trials are being conducted by a number of different research institutions, including the University of Florida and the National Institute of Mental Health.
Side Effects
As with any drug, IDRA-21 has the potential to cause side effects. These can include headache, nausea, and insomnia. However, these side effects are generally mild and tend to subside with continued use of the drug.
